Hot Flashes Mark Perimenopause; Brain Fog at Work Does Not

She is forty-six, and she has read the same four-line email three times without retaining any of it. The meeting is in ten minutes and the word she wants for a thing she has explained a hundred times is simply not there. This has been happening since roughly March. The week's headlines have an explanation ready, and it is a sympathetic one: midlife hormones, a workplace that was never built for them, a cost measured in careers. The explanation is tempting partly because it is kind, and partly because the alternative is that something else is wrong.

What the coverage tends not to supply is the part that would actually help her sort it out: whether the fog is evidence of perimenopause in the first place. That turns out to be an answerable question, and the largest recent attempt to answer it reaches a conclusion that cuts against the headline. The symptoms that interfere most visibly with work are the ones least able to tell a woman where she is in the transition.

The Australian Women's Midlife Years (AMY) Study was a nationally representative cross-sectional survey of women aged 40 to 69, recruited through a non-probability panel using both online and offline sources between 27 October 2023 and 19 March 2024. Eligibility required completing the questionnaire in English. It was funded by Australia's National Health and Medical Research Council, and 8,096 women were recruited in total.

Symptoms were measured with the Menopause-specific Quality of Life questionnaire (MENQOL), covering bother over the previous four weeks. Participants were then staged by the STRAW+10 criteria, which define the transition by changes in menstrual cycle frequency. Of the 8,096, some 5,509 could be staged that way: 1,250 premenopausal, 344 early perimenopausal, 271 late perimenopausal, and 3,644 postmenopausal. Prevalence ratios were adjusted for age, body-mass index and other demographic variables.

The design point worth holding onto is that STRAW+10 staging is the yardstick here, not the thing being tested. The researchers' question was which symptoms line up with that menstrual staging well enough to flag the onset of the transition in women whose cycles cannot be read — those with infrequent or absent periods, for whom the standard definition simply does not work.

Hot flushes, which the papers call vasomotor symptoms, showed by far the largest shift. Moderate-to-severe hot flushes went from 8.8% of premenopausal women (95% CI 7.2 to 10.4) to 37.3% in late perimenopause (95% CI 31.5 to 43.0), an adjusted prevalence ratio of 4.74 (95% CI 3.64 to 6.19). Among sexual symptoms, vaginal dryness was the most discriminating, with an adjusted prevalence ratio of 2.54 (95% CI 1.78 to 3.61) from premenopause to late perimenopause.

Everything else was comparatively flat. The authors report less variation across stages for the other symptoms, poor memory and low mood among them. That is the finding that matters for the woman staring at her inbox: the complaint she most wants explained is the one that distinguishes a premenopausal woman from a late-perimenopausal one least well.

There is an important qualification, and it concerns pairings rather than single symptoms. Women who had both vasomotor symptoms and changed menstrual flow reported more moderately-to-severely bothersome symptoms than women without vasomotor symptoms. And compared with premenopausal women who had vasomotor symptoms and changed flow, early perimenopausal women with vasomotor symptoms did report more poor memory, at an adjusted prevalence ratio of 1.36 (95% CI 1.06 to 1.75). Fog alongside hot flashes carries information. Fog on its own carries much less.

A second analysis of the same cohort, published in BMJ Sexual and Reproductive Health in 2026, went after the quieter case: women reporting no vasomotor symptoms whatsoever. Of 1,039 such respondents, 660 (63.5%) had regular periods with no change in flow, 209 (20.1%) had regular periods with changed flow — the late reproductive stage — and 170 (16.4%) were perimenopausal by cycle variation of at least seven days.

Four symptoms separated the unchanged-flow group from the changed-flow group, each of them in the direction of changed flow being worse: poor memory (adjusted prevalence ratio 0.60, 95% CI 0.43 to 0.83), "accomplishing less than used to" (0.65, 95% CI 0.50 to 0.85), "feeling tired or worn out" (0.78, 95% CI 0.68 to 0.90) and bloating (0.63, 95% CI 0.49 to 0.80). The other 18 symptoms the questionnaire asks about showed no difference between the late reproductive stage and early perimenopause.

The authors' reading was deflationary: women with regular cycles and changed flow but no hot flashes differ little from women with unchanged flow, which means a change in flow by itself is not a clear indicator that the transition has begun. Notably, three of the four symptoms that did separate are the work-shaped ones — memory, getting less done, exhaustion — and they separated by modest margins inside a comparison the authors judged, overall, to be weak.

None of this makes the fog imaginary. MENQOL asks about "accomplishing less than used to" because that is a thing women report, and in this cohort many did. A symptom that fails to mark a hormonal stage can still be severe, measurable and worth clinical attention; those are two different claims, and the research literature keeps them apart more carefully than the coverage does.

The AMY authors drew the practical conclusion themselves. Moderate-to-severe vasomotor symptoms can reliably indicate that perimenopause has begun in women whose cycles give no answer. For the other symptoms, they wrote that although menopause might cause or worsen them, other contributing factors need to be considered and included in management and care — and that treatment options and care pathways are what is crucial to improving wellbeing during perimenopause. That is a statement about what clinicians weigh: fatigue, low mood and memory complaints at midlife have a differential diagnosis that does not collapse into one hormonal explanation.

It also sets a boundary around what this evidence can be used for. AMY is an Australian symptom-prevalence study. It observed no workplaces, measured no job performance, and speaks to no country's employment law or accommodation rules. The work framing belongs to the coverage; the study underneath it is about which symptoms track a menstrual stage.

The useful finding here is the deflationary one, and it deserves more airtime than it gets. Brain fog is simultaneously the symptom most readily attributed to perimenopause and the symptom least able to confirm it, and a clinical culture that treats fog as the signature of midlife hormones gets that wrong in both directions at once: it can hand a woman a hormonal story for a thyroid problem, anaemia, sleep apnoea, iron deficiency or depression, and it can also let a real, documented, measurable symptom be filed as a vague midlife complaint that no one owes anything to. The AMY data support a narrower and more honest claim — hot flashes are the stage marker, vaginal dryness is the next best one, and the rest of the list is a set of things that are common at midlife, sometimes worsened by the transition, and best explained on their own terms rather than assumed into a category. What stands out is that the authors did not stop at better labelling. Their stated conclusion was that care pathways and treatment options are the gap, which reads as a quiet verdict on a decade of midlife health coverage that has been far more interested in naming the transition than in what happens to the woman who has named it and still cannot find her word in a meeting.